Ethan Wu

(Chief Executive Officer)

Mr. Wu has led over 20 strategic mergers, acquisitions and joint ventures across China, the US, Italy, Spain and India. Businesses acquired include API companies, generics and specialties. Mr. Wu has deep understanding of Chinese pharmaceutical strategic related cross-border transactions and has rich experience of post-acquisition integrations.


Jinming Liao

(Partner,Chairman of the advisory committee)

Mr. Liao has nearly 40 years of operational experience in the pharmaceutical industry. From zero to one then huge success, Mr. Liao is the pioneer among his peer Chinese executives who has built successful US branches for Chinese pharmaceutical players ever since the 1990s. Mr. Liao is a leading expert in pharmaceutical company cross-border strategy, business development and operations. He is now LTC Global Partner, leading our Princeton office.


Pedram Alaedini


Pharmaceutical executive with extensive experience at large and small companies managing a full spectrum of life sciences supply chain, business development, manufacturing and technical operations, engineering, product development, and quality improvement. Held positions at American and European life science companies, generic manufacturers, contract service organizations, and consulting firms and worked in the U.S., Europe, South America, and Asia. Chemical engineer with MBA in operations management and six sigma black belt.


Lance Liu


Over 20 years’ experience in the pharmaceutical industry. Worked on pharmaceutical patents and approvals for large pharmaceutical companies such as Pfizer, Celgene and Hengrui. Dr. Liu has helped Pfizer win a $70 million patent lawsuit against Teva and participated in several patent transfer projects between large pharmaceutical companies. Dr. Liu initiated the $600,000 fixed-cost P-IV patent litigation defense. In the past few years, he has completed 16 small-scale generic P-IV Certifications for several Chinese pharmaceutical companies in the US FDA.


Robert Bloder


Over 30 years’ experience in the pharmaceutical industry. Mr. Bloder led the strategic transition and product licensing in Apotex as Vice President Global Business Development, falicitated the acquistion of Aveva and built the US Business Development team for Apotex. He also has served in Pfizer with responsibilities in strategic planning, business development, marketing and sales management, and launched many blockbuster and first-in-class products like Lipitor, Neurontin, Cognex, Nipent and Rezulin for Pfizer.


Amy Xu

(Investment Director)

Amy Xu has nearly a decade’s experience with one of the biggest global private equity asset managers and has taken various investment roles in Europe, Asia and the US. Ms. Xu has successfully closed over 20 private equity and venture investments across Asia Pacific, Europe, South America and the US. Ms. Xu is an expert in cross-border private equity transactions and asset management operations.


Marc Roualet

(Chief Legal Director)

Mr. Roualet has provided counsel for over 20 strategic mergers, acquisitions, joint ventures and equity and debt financings across the United States, Asia, Europe and the Middle East. Mr. Roualet worked as a transactional attorney for an international law firm and is skilled at providing business-minded legal advice.